Form 4: Abbott Laboratories Executive Vice President Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Philip P. Boudreau, Executive Vice President of Abbott Laboratories, reports a transaction involving common shares on September 1, 2024.
Summary
- On September 1, 2024, Philip P. Boudreau, an Executive Vice President at Abbott Laboratories, reported a transaction involving the company's common shares.
- The transaction involved the disposal of 387 common shares at a price of $113.27.
- Following the transaction, Boudreau directly owns 38,966 common shares.
- Boudreau also indirectly owns 356 common shares through a Profit Sharing Trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard SEC filing reporting a transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in company stock. It allows investors to monitor the actions of key executives and their confidence in the company's prospects.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the actions of company executives.
Key Dates
| Date | Description |
|---|---|
| 09/01/2024 | Date of transaction involving common shares. |
| 09/01/2024 | Balance in the Abbott Laboratories Stock Retirement Trust as of this date. |
| 09/04/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.